Nothing Special   »   [go: up one dir, main page]

MX2013001612A - Moduladores de trpv3 novedosos. - Google Patents

Moduladores de trpv3 novedosos.

Info

Publication number
MX2013001612A
MX2013001612A MX2013001612A MX2013001612A MX2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A MX 2013001612 A MX2013001612 A MX 2013001612A
Authority
MX
Mexico
Prior art keywords
novel
trpv3
trpv3 modulators
modulators
compositions
Prior art date
Application number
MX2013001612A
Other languages
English (en)
Inventor
Michael E Kort
Arthur Gomtsyan
Erol K Bayburt
Jerome F Daanen
Philip R Kym
Bruce Clapham
Eric A Voight
Phil B Cox
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013001612A publication Critical patent/MX2013001612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente solicitud se describen moduladores de TRPV3 de la fórmula (I), en la cual G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, y p son como se definen en la descripción. También se presentan composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones.
MX2013001612A 2010-08-10 2010-08-10 Moduladores de trpv3 novedosos. MX2013001612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/001213 WO2012019315A1 (en) 2010-08-10 2010-08-10 Novel trpv3 modulators

Publications (1)

Publication Number Publication Date
MX2013001612A true MX2013001612A (es) 2013-07-05

Family

ID=45567252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001612A MX2013001612A (es) 2010-08-10 2010-08-10 Moduladores de trpv3 novedosos.

Country Status (13)

Country Link
US (1) US9156788B2 (es)
EP (1) EP2603490A4 (es)
JP (1) JP2013538800A (es)
KR (1) KR20130097748A (es)
CN (1) CN103140476A (es)
AU (1) AU2010359001A1 (es)
BR (1) BR112013003121A2 (es)
CA (1) CA2807538A1 (es)
CR (1) CR20130106A (es)
MX (1) MX2013001612A (es)
RU (1) RU2013110324A (es)
SG (1) SG187811A1 (es)
WO (1) WO2012019315A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
US9921187B2 (en) 2011-01-20 2018-03-20 Northeastern University Real-time pavement profile sensing system using air-coupled surface wave
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
CN104254522A (zh) * 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
WO2013062964A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN109942459B (zh) * 2017-12-21 2022-06-24 南京理工大学 一种合成3-二氟甲基-3-丙烯腈类化合物的方法
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138547A (en) * 1978-04-14 1979-10-27 Takeda Chem Ind Ltd Beta-aminoketone derivative and its preparation
JPS60109539A (ja) * 1983-11-15 1985-06-15 Sumitomo Chem Co Ltd ベンジルアルコ−ル誘導体
JPS60230742A (ja) * 1984-04-28 1985-11-16 Shinko Electric Co Ltd ル−プ式デ−タ伝送方式における割込み信号伝送方法
JPS6471830A (en) * 1987-09-11 1989-03-16 Rikagaku Kenkyusho Monofluorocyclobutanes and production thereof
DE3914820A1 (de) 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4018260A1 (de) * 1990-06-07 1991-12-12 Basf Ag Derivate des (beta)-picolins und diese enthaltende pflanzenschutzmittel
DE4318916A1 (de) * 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) * 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1215715A (zh) * 1997-10-28 1999-05-05 兰州大学 立体选择性1,3－二醇合成方法
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
JP2002502844A (ja) * 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
EP1318988A2 (en) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
US7282591B2 (en) * 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
PL376659A1 (pl) 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
CA2608194A1 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CA2628441A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
BRPI0909737A2 (pt) * 2008-03-20 2019-03-06 F. Hoffmann-La Roche Ag compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
MX2010011762A (es) * 2008-06-17 2011-02-03 Glenmark Pharmaceuticals Sa Derivados de cromano como moduladores del trpv3.
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
WO2010110231A1 (ja) * 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
ES2516165T3 (es) 2010-07-12 2014-10-30 F. Hoffmann-La Roche Ag 1-hidroxiimino-3-fenil-propanos
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
WO2013062964A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators

Also Published As

Publication number Publication date
RU2013110324A (ru) 2014-09-20
WO2012019315A1 (en) 2012-02-16
EP2603490A1 (en) 2013-06-19
CA2807538A1 (en) 2012-02-16
SG187811A1 (en) 2013-03-28
US9156788B2 (en) 2015-10-13
AU2010359001A1 (en) 2013-03-14
CR20130106A (es) 2013-07-19
CN103140476A (zh) 2013-06-05
JP2013538800A (ja) 2013-10-17
US20130150409A1 (en) 2013-06-13
KR20130097748A (ko) 2013-09-03
EP2603490A4 (en) 2014-01-01
BR112013003121A2 (pt) 2016-06-28

Similar Documents

Publication Publication Date Title
PH12018501711A1 (en) Compounds for treating spinal muscular atrophy
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2013011054A (es) Antagonistas de trpvi.
IN2012DN03883A (es)
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
IN2015DN00960A (es)
MX352962B (es) Compuestos para tratar atrofia muscular espinal.
MX2013001612A (es) Moduladores de trpv3 novedosos.
MX2014002770A (es) Nuevos derivados dihidroquinolina-2-ona.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MY169267A (en) New aryl-quinoline derivatives
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
TN2009000536A1 (en) Novel herbicides
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2011010046A (es) Derivados de diaminopteridina.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal